MACK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MACK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Merrimack Pharmaceuticals's EBIT per Share for the three months ended in Mar. 2024 was $-0.05. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.16.
During the past 3 years, the average EBIT per Share Growth Rate was 26.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 52.00% per year. During the past 10 years, the average EBIT per Share Growth Rate was 40.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Merrimack Pharmaceuticals's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Merrimack Pharmaceuticals was 65.90% per year. The lowest was -4.50% per year. And the median was 30.25% per year.
Merrimack Pharmaceuticals's EBIT for the three months ended in Mar. 2024 was $-0.67 Mil.
The historical data trend for Merrimack Pharmaceuticals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merrimack Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EBIT per Share | Get a 7-Day Free Trial | -1.59 | -0.38 | -0.20 | -0.16 | -0.15 |
Merrimack Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EBIT per Share | Get a 7-Day Free Trial | -0.04 | -0.04 | -0.04 | -0.03 | -0.05 |
EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.
Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.
Merrimack Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as
EBIT per Share | (A: Dec. 2023 ) | ||
= | EBIT | / | Shares Outstanding (Diluted Average) | = | -2.176 | / | 14.299 |
= | -0.15 |
Merrimack Pharmaceuticals's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as
EBIT per Share | (Q: Mar. 2024 ) | ||
= | EBIT | / | Shares Outstanding (Diluted Average) | = | -0.669 | / | 14.452 |
= | -0.05 |
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merrimack Pharmaceuticals (NAS:MACK) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Thank you for viewing the detailed overview of Merrimack Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Eric Andersen | director, other: See Remarks | 1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404 |
Gary L Crocker | director, officer: President | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
Noah G. Levy | director, other: See Remarks | 60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165 |
Ana Radeljevic | director | 2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467 |
Ulrik B. Nielsen | director | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
Russell T Ray | director | 2525 DUPONT DR, IRVINE CA 92612 |
Newtyn Capital Partners, Lp | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
Ledo Capital, Llc | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
Newtyn Te Partners, Lp | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
Newtyn Partners, Lp | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
Western Standard Partners Qp, L.p. | other: See Remarks | 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036 |
Western Standard Partners Lp | other: See Remarks | 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036 |
Western Standard Llc | other: See Remarks | 5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036 |
Newtyn Management, Llc | other: See Remarks | 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
22nw Gp, Inc. | 10 percent owner, other: See Explanation of Responses | 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107 |
From GuruFocus
By PRNewswire PRNewswire • 04-05-2019
By PRNewswire PRNewswire • 09-25-2019
By Business Wire Business Wire • 11-04-2021
By PRNewswire PRNewswire • 03-06-2019
By Business Wire Business Wire • 08-03-2022
By Business Wire Business Wire • 11-05-2020
By GuruFocus Research GuruFocus Editor • 08-15-2022
By Business Wire Business Wire • 03-11-2021
By Business Wire Business Wire • 12-05-2022
By PRNewswire PRNewswire • 05-10-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.